Strategy Asset Managers’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-5,270
| Closed | -$590K | – | 278 |
|
|
2021
Q4 | $590K | Buy |
5,270
+1,335
| +34% | +$149K | 0.15% | 118 |
|
|
2021
Q3 | $495K | Buy |
3,935
+157
| +4% | +$19.8K | 0.11% | 155 |
|
|
2021
Q2 | $512K | Sell |
3,778
-345
| -8% | -$46.8K | 0.11% | 149 |
|
|
2021
Q1 | $559K | Buy |
4,123
+201
| +5% | +$27.3K | 0.13% | 129 |
|
|
2020
Q4 | $552K | Buy |
3,922
+210
| +6% | +$29.6K | 0.13% | 127 |
|
|
2020
Q3 | $413K | Buy |
3,712
+202
| +6% | +$22.5K | 0.11% | 150 |
|
|
2020
Q2 | $393K | Buy |
3,510
+275
| +9% | +$30.8K | 0.11% | 150 |
|
|
2020
Q1 | $250K | Buy |
+3,235
| New | +$250K | 0.08% | 164 |
|
|
2019
Q2 | – | Sell |
-185
| Closed | -$17K | – | 203 |
|
|
2019
Q1 | $17K | Buy |
+185
| New | +$17K | ﹤0.01% | 183 |
|